GlassScriptPhysician profile
John T Ogden
NPI 1801832738
$10,738.45
in general payments reported to CMS, 2019-2025
12 companies · $3,518 in 2025
The $3,518 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $1,272 · 2021: $1,056 · 2022: $2,016 · 2023: $1,486 · 2024: $940 · 2025: $3,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,558 · Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,557.72 |
| Food and Beverage | $2,385.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,293.80 | 2019-2025 | |
| Titan Surgical Group, LLC | $2,913.79 | 2020-2025 | |
| Stryker Corporation | $2,291.22 | 2020-2025 | Mako, Tritanium, Blueprint Patient Specific Instrumentation |
| Medical Device Business Services, INC. | $1,628.39 | 2025 | Velys, Attune |
| Depuy Synthes Sales INC. | $183.82 | 2019-2025 | Attune |
| Becton, Dickinson and Company | $155.45 | 2025 | Arista |
| Shoulder Innovations, INC. | $62.97 | 2025 | Inset System |
| Ferring Pharmaceuticals INC. | $62.20 | 2019-2020 | |
| Wright Medical Technology, INC. | $58.88 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $55.05 | 2019-2025 | Iovera |
| Bioventus LLC | $16.67 | 2023 | Durolane |
| Fidia Pharma USA INC. | $16.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.